ClinicalTrials.gg
TerminatedNCT00295490Updated Sep 12, 2011Results posted

Trial Evaluating Devil's Claw for the Treatment of Hip and Knee Osteoarthritis

A Phase 2 interventional study of Devil Claw and Placebo in Osteoarthritis, Knee and Osteoarthritis, Hip, sponsored by University of Southampton. Terminated at 1 site in United Kingdom. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2011-09-12.

Sponsored by University of Southampton · Phase 2, Interventional, and Treatment

How we know

Why this study was terminated
unexpected withdrawal of funding

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
67
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 112 studies in Osteoarthritis, Knee with a site in United Kingdom — 12 open to participants now, 21 under way, none of them phase 3. Osteoarthritis, Knee · United Kingdom.

Enrollment
51st of 90
67 · median 80
Started
2004
with 1 other
Phase 2
10 of 112
none open now
Registered
7th of 112
by date

Among the 112 studies in Osteoarthritis, Knee with a site in United Kingdom, this one is the 51st largest by enrollment of the 90 interventional ones that give a count, is one of 2 that started in 2004, is one of 10 in phase 2, and was the 7th registered.

Osteoarthritis, Knee

3,297 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.

Browse Osteoarthritis, Knee studies →

Open to participants now

12 of the 112 studies in Osteoarthritis, Knee with a site in United Kingdom are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 384 Osteoarthritis, Knee studies recruiting now, 178 (46%) set no upper age limit and 113 (29%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 112 studies in Osteoarthritis, Knee with a site in United Kingdom, or all of them as a file.
02

Study summary

Osteoarthritis of both the knee and hip joints are common conditions; knee osteoarthritis affects 6% of adults over 30 years of age and osteoarthritis of the hip affects between 3% and 6% of the Caucasian population. Both forms of osteoarthritis are associated with disability. Conventional treatment (analgesics and the use non-steroidal anti-inflammatory, NSAIDS) is prophylactic, aimed at decreasing pain and improving function. However long term use of NSAIDS is associated with a high incidence of adverse events (gastrointestinal tract symptoms). A safer alternative treatment would therefore be beneficial.

Both anecdotal evidence and recent studies have implicated the potential of the herbal remedy Devil's Claw (Harpagophytum procumbens) for the treatment of painful, chronic arthritic type conditions (Ernst and Chrubasik, 2000). Devil's Claw is an extract obtained from the root of the Harpagophytum procumbens plant, a member of the sesame family found in the Kalahari region in South Africa. It has been shown that this herbal remedy has anti-inflammatory and analgesic effects (Baghdikian et al, 1997). Currently Devil's Claw is marketed for use as a supportive treatment of degenerative arthrosis, is not a Medicines Control Agency licensed product and is freely available to the general public in health food stores and pharmacies.

The objectives of this study are to assess the efficacy, optimum dosage and safety of the herbal remedy Devil's Claw (Harpagophytum) in the treatment of osteoarthritis of the knee and/or hip. The primary objective of this study is to investigate the following three principal questions:

  1. To compare the efficacy of Devil's Claw with placebo in the treatment of osteoarthritis of the knee and/or hip
  2. To determine the optimum dose of Devil's Claw and
  3. To evaluate the safety and tolerability of three doses of Devil's Claw in the treatment of osteoarthritis of the knee/hip and to compare them to placebo There are also a number of secondary research objectives that will also be addressed (see later).

These objectives are based on the following hypotheses :

Hypotheses

  • Devil's Claw has anti-inflammatory properties (as assessed by the reduction in pain, stiffness and disability aspects on the WOMAC) in chronic osteoarthritis of the knee and/or hip after 16 weeks of treatment, as compared to placebo.
  • A dose response effect exists in the treatment of osteoarthritis of the knee/hip by Devil's Claw.
Read the detailed description

STUDY DESIGN: Randomized, placebo-controlled, dose-ranging two-centre study PREPARATIONS FOR INVESTIGATION: Devil's Claw (Allya®)/placebo as tablets

STATISTICAL METHODS:

Analysis on an intention to treat basis.

The following tests will be performed and all statistical significance will be set at p \< 0.05:

Primary efficacy analysis: The primary outcome will be the reduction in WOMAC total score from baseline to week 16. The week 16 means for the four treatment groups will be compared using an analysis of covariance taking account of baseline assessments and any demographic differences, age, gender, etc, which are found to be significant. Multiple comparison tests will be used to examine specific differences of initially specified interest, such as the two highest doses of Devil's Claw versus placebo.

Secondary Efficacy Analysis: Similar analyses of covariance will be used to examine treatment group differences at week 16 compared with baseline for WOMAC subscales (pain, stiffness and physical function), and Quality of Life assessments (SF-36). Changes in the subject's well-being and overall global assessment will be compared using appropriate non-parametric tests, e.g. Mann-Whitney test or MacNemar's test. Changes in attitudes and health beliefs to CAM will be assessed using Chi-Squared tests.

Safety Evaluation: Group differences between adverse event reporting will be assessed by descriptive methods.

NUMBER OF PATIENTS:

264 (50 patients in each group, with an expected total of 64 drop-outs) NUMBER OF SITES: 2

TIME SCHEDULE:

Study Start: April 2004 Study End: March 2007 Observation period/patient: 20 weeks

03

Conditions studied

  • Osteoarthritis, Knee
  • Osteoarthritis, Hip

Keywords

  • double blind randomised controlled trial
  • phase II
  • Devil's Claw
  • osteoarthritis of the knee
  • osteoarthritis of the hip
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with either a pragmatic diagnosis of osteoarthritis of the knee, with no other known rheumatological condition and who report the following clinical features (based on the ACR classification for knee OA1):

    • knee pain on most days of the previous month
    • morning stiffness of less than 30 minutes duration
    • "stiffness" in resting the joint and and are aged over 40 years
  • osteoarthritis of the hip, with no other known rheumatological condition and who report the following clinical features (based on the ACR classification for hip OA2):

    • hip pain on most days of the previous month and at least two of the following 3 features:
    • ESR \< 20mm/hour
    • Radiographic femoral or acetabular osteophytes
    • Radiographic joint space narrowing (superior, axial and/or medial)
    • And are aged over 45 years of age
  • The diagnosis of osteoarthritis will be confirmed by X-ray. Only patients who have grade 2 to 4 of the Kellgren and Lawrence scale will be recruited. (The Kellgren and Lawrence scale ranges from grade 0 to grade 4 where grades 0 and 1 represent doubtful osteoarthritic changes and therefore a doubtful diagnosis.)
  • Patients who have been on stable medication (conventional or complementary, including nutritional medicine) for the past three months, but are still getting symptoms (incomplete responders)
  • Only those patients who record baseline pain scores on the WOMAC scale of at least 20 mm on the VAS for a minimum of 6 out of 7 days monitored during the period from Clinic Visit 1 (screening) and Clinic Visit 2 (baseline)
  • Ability to comply with the requirements of the study and to give
  • For women of : negative pregnancy test

Exclusion criteria

Exclusion Criteria:

  • Participation in an trial within 30 days prior to enrollment
  • Previous treatment with Devil' s Claw within 90 days prior to enrollment
  • Patients awaiting a replacement knee or hip joint
  • Patients with other conditions that cause pain
  • Patients with congenital dislocation of the hip
  • Patients who have had operations on their hip due to previous trauma
  • Patients with severe co-morbidities - including severe cardiac or pulmonary disease and cancer
  • Dementia, psychoses, or other significant impairment of mental status that would prohibit sufficient comprehension, provision of and to allow undertaking of the necessary self-care or toxicity reporting
  • Patients taking medication
  • Known allergies against any of the ingredients of the treatments
  • Patients who would be unable to complete the self assessment forms, or to attend for X-ray and clinical examination
  • Patients with other known rheumatic disease such as rheumatoid arthritis
  • Patients with the diagnosis gout
  • Patients who report a red or hot swollen joint (which is unlikely to be due to OA), and would require further rheumatological assessment
  • Patients with conditions known to be to the study medication i.e. patients with gastric or duodenal ulcers; gallstones; patients taking drugs for arrhythmias; patients with heart failure
  • Patients who are pregnant, trying to become pregnant or breastfeeding
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
67 participants (actual)

Study arms

  • Experimental
    240mg Devil claw

    Sub clinical dose if the 3 doses employed

    Drug: Devil Claw

  • Experimental
    960mg Devil Claw

    Active dose

    Drug: Devil Claw

  • Experimental
    1920 mg Devil claw

    Active dose

    Drug: Devil Claw

  • Placebo comparator
    Placebo

    Comparator for all active intervention arms

    Drug: Placebo

Interventions

  • DrugHarpagophytum procumbensStudies of Harpagophytum procumbensHarpagophytum procumbens pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Dose ranging study so will elucidate dose Frequency is four times daily

    Also known as: Harpagophytum procumbens

  • DrugPlacebo

    Placebo has same dosing freq as for active intervention and for same time period

06

What researchers measure

Primary outcomes

  1. Western Ontario and Mc Master University OA Index (WOMAC)

    WOMAC is a disease specific outcome measure for osteoarthritis. It has three subscales assessing pain (5 questions), stiffness (2 questions) and function (15 questions). together the subscales give an overall total score ranging from 0 (worst) to 100 (best; an increase in total score indicates an improvement in health. THe outcome was measured at baseline, week 8 and week 16. In this study the primary outcome was the reduction in WOMAC total score from baseline to the end of treatment at week 16.

    Time frame: Baseline, week 8 and week 16

Secondary outcomes

  1. Pain Subscale on Western Ontario and Mc Master University OA Index

    Subscale assessed by 100mm VAS based on five questions addressing pain in osteoarthritis using the terminators no pain (0mm) to extreme pain (100mm). a higher score therefore indicates more severe pain. This outcome was recorded at baseline, week 8 and week 16 (end of treatment). The outcome for this study was reported as the change in WOMAC pain score from baseline to end of treatment at week 16.

    Time frame: Baseline, week 8 and week 16

  2. Disability Subscale on The Western Ontario and Mc Master University OA Index

    Subscale assessed by 100mm VAS based on twelve questions addressing disability in osteoarthritis with a higher score indicating worse symptoms. The VAS used terminators of no disability (0mm) to extreme disability (100mm). The measure was recorded at baseline, week 8 and week 16. We reported the outcome as the change from baseline to end of treatment at week 16.

    Time frame: baseline, 8 and 16 weeks

  3. Stiffness Subscale on the The Western Ontario and Mc Master University OA Index

    Subscale assessed by 100mm VAS based on two questions addressing stiffness in osteoarthritis;a higher score indicating worse symptoms. The VAS used terminators of no stiffness (0mm) to extreme stiffness (100mm). The measure was recorded at baseline, week 8 and week 16. We reported the outcome as the change from baseline to end of treatment at week 16.

    Time frame: Baseline, week 8 and week 16

  4. Short Form-36 (SF-36)

    Quality of Life assessment containing 8 scales clustered into 2 summary scales: physical health and mental health. Each question is scored out from 0 (indicating worst health) to 100 (indicating best health). Mean scores for the 8 scales (total scores/no questions completed) are calculated to give a total score for each of the two summary scales between 0 (worst health) and 100 (best health). SF36 was recorded at baseline, week 8 and at the end of treatment at week 16. we reported the change from baseline to end of treatment as the outcome.

    Time frame: Baseline, week 8 and week 16

  5. Patient Global Assessment

    To assess changes in the subject's well-being based on 7 point likert scale ranging from very poor (0 point) to very good (7 point). Outcome was recorded at baseline, week 8 and end of treatment at week 16. We reported outcome as the change in patient global assessment from baseline to end of treatment at week 16.

    Time frame: Baseline, week 8 and week 16

  6. Complementary and Alternative Medicine Beliefs Inventory

    Questionnaire to assess changes in attitudes and health beliefs to CAM.the questionnaire as 17 questions, each scored on a 7 point likert scale from strongly disagree to strongly agree; a higher score indicates stronger belief in the measure. Minimum score 17, maximum score 119

    Time frame: four monthly

  7. Adverse Event Reporting

    To identify Group differences between the number of adverse event recorded by patient for both serious and non serious adverse events, as well as events considered being attributable to the study medication.

    Time frame: Baseline and weeks 2,4,6,8,12 and 16

07

Results

Posted Sep 9, 2011

Participant flow

Recruited during 2004 to 2007 Recruitment location: From GP clinics and from adverts in the media

Participant flow — Overall Study
Milestone240mg Devil Claw960mg/d Devil Claw1,920mg/d Devil ClawPlacebo
Started15191617
Completed14151212
Not completed1445
Withdrew: Protocol violation0033
Withdrew: Withdrawal by subject0201
Withdrew: Lost to follow-up0010
Withdrew: Adverse event1000
Withdrew: Other0201

Outcome measures

PrimaryWestern Ontario and Mc Master University OA Index (WOMAC)

WOMAC is a disease specific outcome measure for osteoarthritis. It has three subscales assessing pain (5 questions), stiffness (2 questions) and function (15 questions). together the subscales give an overall total score ranging from 0 (worst) to 100 (best; an increase in total score indicates an improvement in health. THe outcome was measured at baseline, week 8 and week 16. In this study the primary outcome was the reduction in WOMAC total score from baseline to the end of treatment at week 16.

Time frame:
Baseline, week 8 and week 16
Reported as:
Mean · Unit on 100mm scale

No measurements were reported for this outcome.

SecondaryPain Subscale on Western Ontario and Mc Master University OA Index

Subscale assessed by 100mm VAS based on five questions addressing pain in osteoarthritis using the terminators no pain (0mm) to extreme pain (100mm). a higher score therefore indicates more severe pain. This outcome was recorded at baseline, week 8 and week 16 (end of treatment). The outcome for this study was reported as the change in WOMAC pain score from baseline to end of treatment at week 16.

Time frame:
Baseline, week 8 and week 16
Reported as:
Mean · Unit on 100mm VAS scale

No measurements were reported for this outcome.

SecondaryDisability Subscale on The Western Ontario and Mc Master University OA Index

Subscale assessed by 100mm VAS based on twelve questions addressing disability in osteoarthritis with a higher score indicating worse symptoms. The VAS used terminators of no disability (0mm) to extreme disability (100mm). The measure was recorded at baseline, week 8 and week 16. We reported the outcome as the change from baseline to end of treatment at week 16.

Time frame:
baseline, 8 and 16 weeks
Reported as:
Mean · unit on 100mm VAS scale

No measurements were reported for this outcome.

SecondaryStiffness Subscale on the The Western Ontario and Mc Master University OA Index

Subscale assessed by 100mm VAS based on two questions addressing stiffness in osteoarthritis;a higher score indicating worse symptoms. The VAS used terminators of no stiffness (0mm) to extreme stiffness (100mm). The measure was recorded at baseline, week 8 and week 16. We reported the outcome as the change from baseline to end of treatment at week 16.

Time frame:
Baseline, week 8 and week 16
Reported as:
Mean · Unit on 100mm VAS scale

No measurements were reported for this outcome.

SecondaryShort Form-36 (SF-36)

Quality of Life assessment containing 8 scales clustered into 2 summary scales: physical health and mental health. Each question is scored out from 0 (indicating worst health) to 100 (indicating best health). Mean scores for the 8 scales (total scores/no questions completed) are calculated to give a total score for each of the two summary scales between 0 (worst health) and 100 (best health). SF36 was recorded at baseline, week 8 and at the end of treatment at week 16. we reported the change from baseline to end of treatment as the outcome.

Time frame:
Baseline, week 8 and week 16
Reported as:
Mean · Unit of scale

No measurements were reported for this outcome.

SecondaryPatient Global Assessment

To assess changes in the subject's well-being based on 7 point likert scale ranging from very poor (0 point) to very good (7 point). Outcome was recorded at baseline, week 8 and end of treatment at week 16. We reported outcome as the change in patient global assessment from baseline to end of treatment at week 16.

Time frame:
Baseline, week 8 and week 16
Reported as:
Mean · Unit on scale (Likert from very poor to

No measurements were reported for this outcome.

SecondaryComplementary and Alternative Medicine Beliefs Inventory

Questionnaire to assess changes in attitudes and health beliefs to CAM.the questionnaire as 17 questions, each scored on a 7 point likert scale from strongly disagree to strongly agree; a higher score indicates stronger belief in the measure. Minimum score 17, maximum score 119

Time frame:
four monthly
Reported as:
Mean · unit on scale

No measurements were reported for this outcome.

SecondaryAdverse Event Reporting

To identify Group differences between the number of adverse event recorded by patient for both serious and non serious adverse events, as well as events considered being attributable to the study medication.

Time frame:
Baseline and weeks 2,4,6,8,12 and 16
Reported as:
Number · Participants

No measurements were reported for this outcome.

Adverse events

Collected over Twenty week period. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
240mg Devil Claw—0/15 (0%)15/15 (100%)
960mg/d Devil Claw—1/19 (5.3%)18/19 (94.7%)
1,920mg/d Devil Claw—0/16 (0%)15/16 (93.8%)
Placebo—0/17 (0%)16/17 (94.1%)
Most frequent serious events
Most frequent serious events
Event240mg Devil Claw960mg/d Devil Claw1,920mg/d Devil ClawPlacebo
Transient blindnessEye disorders0/151/190/160/17
Most frequent other events
Most frequent other events
Event240mg Devil Claw960mg/d Devil Claw1,920mg/d Devil ClawPlacebo
ArthralgiaMusculoskeletal and connective tissue disorders12/1511/199/1611/17
NasopharyngitisRespiratory, thoracic and mediastinal disorders6/157/192/162/17
HeadacheGeneral disorders5/155/193/162/17
DiarrhoeaGastrointestinal disorders3/154/191/161/17
FatigueGeneral disorders1/154/191/162/17
CoughRespiratory, thoracic and mediastinal disorders0/154/192/161/17
Back painMusculoskeletal and connective tissue disorders2/152/193/163/17

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)240mg Devil Claw960mg/d Devil Claw1,920mg/d Devil ClawPlaceboTotal
<=18 years00000
Between 18 and 65 years61311939
>=65 years965828
Age Continuous
Age Continuous(years)240mg Devil Claw960mg/d Devil Claw1,920mg/d Devil ClawPlaceboTotal
Mean65.2 ± 11.959.6 ± 6.959.8 ± 8.463.2 ± 8.661.8 ± 9.1
Sex: Female, Male
Sex: Female, Male(Participants)240mg Devil Claw960mg/d Devil Claw1,920mg/d Devil ClawPlaceboTotal
Female5108932
Male1098835
Region of Enrollment
Region of Enrollment(participants)240mg Devil Claw960mg/d Devil Claw1,920mg/d Devil ClawPlaceboTotal
United Kingdom1519161767
08

Study locations

1 site
  • Wellcome Trust Clinical Research Facility, Southampton General Hospital
    Southampton, Hants SO16 6YD, United Kingdom
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2004, a primary completion of Nov 2007 and a completion of Jun 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2011, 3 years 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 21, 2006
First posted
Feb 23, 2006
Start
Dec 2004
Primary completionActual
Nov 2007
CompletionActual
Jun 2008
Results first posted
Sep 9, 2011
Last update
Sep 12, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 12, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00295490
Collaborators
Pascoe Pharmazeutische Praeparate GmbH
Responsible party
Dr Sarah Brien (Senior Research Fellow, University of Southampton) — Principal investigator
First posted
Feb 23, 2006
Start date
Dec 2004
Primary completion
Nov 2007
Completion
Jun 2008
Results posted
Sep 9, 2011
Last update
Sep 12, 2011

Study contacts

George Lewith, MA MD FRCP
principal investigator · University of Southampton
Sarah Brien, Bsc Msc PhD
principal investigator · University of Southampton

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Harpagophytum procumbens

Start the discussion